Figure 2.

In vitro T cell proliferation in PBMC before the vaccination (C0D1) and after GV1001 vaccination (cycles 2, 4, 7 and 10). Histogram plots showing the division peaks following anti-CD3 (1 µg/mL), anti-CD28 (1 µg/mL), and GV1001 (20 µg/mL) stimulation of carboxy fluorescein diacetate succinimidyl ester (CFSE)-labeled CD3^high cells. Significance was evaluated by one-way ANOVA. **p < 0.01, and ***p < 0.001. In patient no. 11, T cells started to divide (histogram) from the fourth cycle of the GV1001 vaccination, and the CFSE intensity of CD3^high cells also significantly increased from the fourth cycle to the tenth cycle of treatment.